

Summary of resolutions passed by the Pathoplexus Executive Board from 28 Feb Dec 2025 to 18 Jun 2025

Excluding resolutions passed during Executive Board Meetings - please see the meeting summary for these

By majority vote of votes submitted the Pathoplexus Executive Board has passed the following resolutions:

- On 16 May 2025, by 3/3 votes submitted, the Board accepted the following resolution:
To modify the Pathoplexus Terms of Service to clarify that Pathoplexus does not accept in-silico or laboratory construct sequences (ex: for patent purposes), by adding the following section:
“Pathoplexus' aim is to provide pathogen sequences from epidemiological and biological settings (sequences which have a sample setting (human, animal, cell, culture) and sample date). In this regard, we do **not** accept sequences that exist simply as in-silico or laboratory constructs, e.g. for patent purposes. Such synthetic sequences will be [revoked](/docs/how-to/revoke-sequences). We **do** accept vaccine-derived sequences (e.g. sequences obtained after vaccination).”